Gujarat-based manufacturer of medical equipment Sahajanand Medical Technologies (SMT) has raised Rs. 150 crore from Samara Capital Partners..DealSamara Capital Partners invests in SMTValue 150 croreDeal TypePrivate EquitySectorMedical DevicesLaw FirmsLakshmikumaran & Sridharan – SMT; Economic Laws Practice – Samara CapitalPartners/HeadsLakshmikumaran & Sridharan – Sudish Sharma; Economic Laws Practice – Darshan Upadhyay.Lakshmikumaran & Sridharan acted for SMT, through a team led by Executive Partner Sudish Sharma, Principal Associate Vatsal Gaur, and Associate Aman Parnami..Economic Laws Practice represented Samara Capital on the deal, with a team led by Partner Darshan Upadhyay, Joint Partner Amit Manubarwala and Associate Dhairal Shah..SMT is a leading manufacturer of coronary stents. Market reports estimate India’s coronary stent market to reach nearly USD 531 million in revenues by end of 2016 and grow rapidly at 14% CAGR..This investment shall boost SMT’s R&D efforts at offering cutting-edge cardiovascular medical devices and facilitating SMT’s entry into competitive global markets, including US, Western Europe and Japan.
Gujarat-based manufacturer of medical equipment Sahajanand Medical Technologies (SMT) has raised Rs. 150 crore from Samara Capital Partners..DealSamara Capital Partners invests in SMTValue 150 croreDeal TypePrivate EquitySectorMedical DevicesLaw FirmsLakshmikumaran & Sridharan – SMT; Economic Laws Practice – Samara CapitalPartners/HeadsLakshmikumaran & Sridharan – Sudish Sharma; Economic Laws Practice – Darshan Upadhyay.Lakshmikumaran & Sridharan acted for SMT, through a team led by Executive Partner Sudish Sharma, Principal Associate Vatsal Gaur, and Associate Aman Parnami..Economic Laws Practice represented Samara Capital on the deal, with a team led by Partner Darshan Upadhyay, Joint Partner Amit Manubarwala and Associate Dhairal Shah..SMT is a leading manufacturer of coronary stents. Market reports estimate India’s coronary stent market to reach nearly USD 531 million in revenues by end of 2016 and grow rapidly at 14% CAGR..This investment shall boost SMT’s R&D efforts at offering cutting-edge cardiovascular medical devices and facilitating SMT’s entry into competitive global markets, including US, Western Europe and Japan.